ME02652B - Stabilizovana varijanta aktivin iib receptora - Google Patents
Stabilizovana varijanta aktivin iib receptoraInfo
- Publication number
- ME02652B ME02652B MEP-2016-243A MEP24316A ME02652B ME 02652 B ME02652 B ME 02652B ME P24316 A MEP24316 A ME P24316A ME 02652 B ME02652 B ME 02652B
- Authority
- ME
- Montenegro
- Prior art keywords
- polypeptide
- seq
- position corresponding
- group
- sequence
- Prior art date
Links
- 108010059616 Activins Proteins 0.000 title claims 5
- 239000000488 activin Substances 0.000 title claims 5
- 102000005606 Activins Human genes 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims 45
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 28
- 238000006467 substitution reaction Methods 0.000 claims 20
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 102000040430 polynucleotide Human genes 0.000 claims 13
- 108091033319 polynucleotide Proteins 0.000 claims 13
- 239000002157 polynucleotide Substances 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 9
- 108010056852 Myostatin Proteins 0.000 claims 9
- 108010023082 activin A Proteins 0.000 claims 9
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 7
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 206010065687 Bone loss Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 230000020763 muscle atrophy Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000010399 Wasting Syndrome Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000005486 microgravity Effects 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
Claims (27)
1. Izolovani protein koji sadrži stabilizovan polipeptid aktivin ITB receptora, naznačen time da je navedeni polipeptid izabran iz grupe koja se sastoji od:(a) polipeptida koji sadrži sekvencu dalje iznetu u grupi koja se sastoji od SEK ID BR: 4, 6, 12 i 14;(b) polipeptida koji ima najmanje 90% identičnosti sekvence sa (a), pri čemupolipeptid ima W ili Y na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i T na položaju koji odgovara položaju 44 iz SEK ID BR: 2, pri čemu je polipeptid sposoban da veže miostatin, aktivin A, ili GDF-11, i{e) polipeptida koji imaju najmanje 95% identičnosti sekvence sa {a), pri čemupolipeptid ima W ili Y na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i T na položaju koji odgovara položaju 44 iz SEK ID BR: 2, pri čemu je polipeptid sposoban da veže miostatin, aktivin A, ili GDF-11.
2. Protein prema patentnom zahtjevu l, naznačen time što je polipeptid vezan sa najmanje jednim heterolognim proteinom.
3. Protein prema patentnom zahtjevu 2, naznačen time što je heterologni polipeptid IgG Fc domena.
4. Protein prema patentnom zahtjevu 2, naznačen time što je heterologni polipeptid povezan sa polipeptidom pomoću linker sekvence.
5. Protein prema patentnom zahtjevu 4, naznačen time što je linker sekvenca izabrana iz grupe koja se sastoji od sekvenci dalje iznetih u: SEK ID BR: 25, SEK ID BR: 27, SEK ID BR: 38, SEK ID BR: 40, SEK ID BR: 42, SEK ID BR: 44, SEK ID BR: 45, SEK ID BR: 46, SEK ID BR: 48, SEK ID BR: 49 i SEK ID BR: 50.
6. Protein prema patentnom zahtjevu 3, naznačen time što protein sadrži polipeptid izabran iz grupe koja se sastoji od: (a) polipeptida koji sadrži sekvencu dalje iznetu u grupi koja se sastoji od SEK ID BR: 8, 10, 16 i 18; (b) polipeptida koji ima najmanje 90% identičnosti sekvence sa (a), pri čemu polipeptid ima W ili Y na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i T na položaju koji odgovara položaju 44 iz SEK ID BR:2, pri čemu je polipeptid sposoban da veže miostatin, aktivin A, ili GDF-11, i (c) polipeptida koji imaju najmanje 95% identičnosti sekvence sa (a), pri čemu polipeptid ima W ili Y na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i T na položaju koji odgovara položaju 44 iz SEK ID BR:2, pri čemu je polipeptid sposoban da veže miostatin, aktivin A, ili GDF-11.
7. Izolovani protein sadrži sekvencu dalje iznetu u SEK ID BR: 10 l EP 2 370 463 Bl
8. Izolovani proteina sadrži stabilizovani aktivin Im receptora polipeptid (svActRIIB) naznačen time što je navedeni polipeptid izabran iz grupe koja se sastoji od: (a) polipeptida koji sadrži sekvencu dalje iznetu u SEK ID BR: 2, osim pojedinačne aminokiselinske supstitucije na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i pojedinačne aminokiselinske supstitucije na položaju koji odgovara položaju 44 iz SEK ID BR: 2, pri čemu je supstitucija na položaju 28 odabrana iz grupe koji se sastoji od W i Y, i supstitucija na položaju 44 je T; (b) polipeptida koji sadrži sekvencu dalje iznetu u aminokiselinama 19 do 134 iz SEK ID BR: 2, osim pojedinačne aminokiselinske supstitucije na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i pojedinačne aminokiselinske supstitucije na položaju koji odgovara položaju 44 iz SEK ID BR: 2, pri čemu je supstitucija na položaju 28 odabrana iz grupe koji se sastoji od W i Y i supstitucija na položaju 44 je T; (e) polipeptida koji sadrži sekvencu dalje iznetu u aminokiselinama 23 do 134 iz SEK ID BR: 2, osim pojedinačne aminokiselinske supstitucije na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i pojedinačne aminokiselinske supstituciju na položaju koji odgovara položaju 44 iz SEK ID BR: 2, pri čemu je supstitucija na položaju 28 odabrana iz grupe koji se sastoji od W i Y i supstitucija na položaju 44 je T; (d) polipeptida koji sadrži sekvencu dalje iznetu u aminokiselinama 25 do 134 iz SEK ID BR: 2, osim pojedinačne aminokiselinske supstitucije na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i pojedinačne aminokiselinske supstitucije na položaju koji odgovara položaju 44 iz SEK ID BR: 2, pri čemu je supstitucija na položaju 28 odabrana iz grupe koji se sastoji od W i Y i supstitucija na položaju 44 je T; (e) polipeptida koji ima najmanje 80% identičnosti sekvence sa bilo kojom od (a) do (d), osim pojedinačne aminokiselinske supstitucije na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i pojedinačne aminokiselinske supstitucije na položaju koji odgovara položaju 44 iz SEK ID BR: 2, pri čemu je supstitucija na položaju 28 odabrana iz grupe koji se sastoji od W i Y i supstitucija na položaju 44 je T, pri čemu je polipeptid sposoban da veže miostatin, aktivin A, ili GDF-11.
9. Izolovani molekul nukleinske kiseline koji sadrži polinukleotid koji kodira polipeptid prema patentnom zahtjevu 8.
10. Izolovani molekul nukleinske kiseline koji sadrži polinukleotid izabran iz grupe koja se sastoji od: (a) polinukleotida koji kodira polipeptid koji sadrži sekvencu dalje iznetu u grupi koja se sastoji od SEK ID BR: 4, 6, 12 i 14;(b) polinukleotida koji kodira polipeptid koji ima najmanje 90% identičnosti sekvence sa (a), pri čemu polipeptid ima W ili Y na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i T na položaju koji odgovara položaju 44 iz SEK ID BR: 2; i pri čemu je je polipeptid sposoban da veže miostatin, aktivin A, ili GDF-ll ; i (e) polinukleotida koji kodira polipeptid koji ima najmanje 95% identičnosti sekvence sa (a), pri čemu polipeptid ima W ili Y na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i T na položaju koji odgovara položaju 44 iz SEK ID BR: 2 i pri čemu je polipeptid sposoban da veže miostatin, aktivin A, ili GDF-11.
11. Moleku!nukleinske kiseline prema patentnom zahtjevu 10, naznačen time što polinukleotid ima sekvencu izabranu iz grupe koja se sastoji od sekvence dalje iznete u SEK ID BR: 3, 5, ll i 13 ili njenog komplementa.
12. Molekul nukleinske kiseline prema patentnom zahtjevu 10, naznačen time što polinukleotid dalje sadrži polinukleotid koji kodira najmanje jedan heterologni protein.
13. ji od:opolinukleotida koji kodira polipeptid koji sadrži sekvencu dalje iznetu u grupi koja se sastoji od SEKR: 8, 10, 16, i 18;b) polinukleotida koji kodira polipeptid koji ima najmanje 90% identičnosti sekvence sa (a), pri čem olipeptid ima W ili Y na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i T na položaju koji odgovar oložaju 44 iz SEK ID BR: 2 i pri čemu je je polipeptid sposoban da veže miostatin, aktivin A, ili GDF-ll ;(e) polinukleotida koji kodira polipeptid koji ima najmanje 95% identičnosti sekvence sa (a), pri čem olipeptid ima W ili Y na položaju koji odgovara položaju 28 iz SEK ID BR: 2 i T na položaju koji odgovar oložaju 44 iz SEK ID BR: 2 i pri čemu je je polipeptid sposoban da veže miostatin, aktivin A, ili GDF-l l.
14. Moleku!l nukleinske kiseline prema patentnom zahtjevu 13, naznačen time što polinukleotid ima sekvencu izabranu iz grupe koja se sastoji od sekvence dalje iznete u SEK ID BR: 7, 9, 15 i 17, ili njenog komplementa.
15. Molekul nukleinske kiseline prema patentnom zahtjevu 10, naznačen time, što je polinukleotid operativno vezan sa transkripcionom ili translacionom regulatornom sekvencom.
16. Rekombinantni vektor koji sadrži moleku! nukleinske kiseline prema patentnom zahtjevu l0.
17. Ćelija domaćin koja sadrži rekombinantni vektor prema patentnom zahtjevu 16.
18. Ćelija domaćin prema patentnom zahtjevu 17, gde je ćelija domaćin ćelija sisara.
19. Postupak proizvodnje svActRiffi proteina koji obuhvata kultivisanje ćelije domaćina prema patentnom zahtjevu 17, pod uslovima koji promovišu ekspresiju proteina i oporavak proteina.
20. Farmaceutska kompozicija koja sadrži efikasnu količinu proteina prema bilo kom od patentnih zahtjeva 1-8 u smeši sa farmaceutski prihvatljivim nosačem.
21. Kompozicija prema patentnom zahtjevu 20 za upotrebu kao lijek.
22. Kompozicija prema patentnom zahtew 20 za upotrebu u postupku liječenja mišićne atrofije ili metaboličkog poremećaja izabranog od dijabetesa, gojaznosti, hiperglikemije ili gubitka koštane mase kod subjekta kome je potreban takav tretman.
23. Kompozicija za upotrebu prema patentnom zahtjew 22, pri čemu je mišićna atrofija usled bolesti gubitka mišićne mase izabrana od mišićne distrofije, amiotrofue lateralne skleroze, kongestivne opstruktivne bolesti pluća, hronične srčane insuficijencije, kaheksije usled kancera, AIDS-a, bubrežne insuficijencije, uremije, reumatoidnog artritisa, sarkopenije uzrokovane starenjem, atrofije organa, sindroma karpalnog tunela, gubitka androgena, opekotina, dijabetesa i atrofije mišića usled dugotrajnog ležanja u krevetu, povrede kičmene moždine, šloga, preloma kostiju, starenja ili izloženosti mikrogravitaciji.
24. Kompozicija prema patentnom zahtjew 20 za upotrebu u postupku liječenja oboljenja u kome je aktivin prekomemo eksprimiran kod subjekta kome je potreban takav tretman i gde je oboljenje kancer.
25. Vektor prema patentnom zahtjew 16 za upotrebu u postupku liječenja gubitka mišićne mase ili metaboličkog poremećaja izabranog od dijabetesa, gojaznosti, hiperglikemije ili gubitka koštane mase ili kancera u kome je aktivin prekomerno eksprimiran kod subjekta kod koga postoji potreba za takvim tretmanom, naznačen time da je vektor sposoban da usmerava ekspresiju svActRIIB polipeptida kod subjekta.
26. Kompozicija za upotrebu prema patentnom zahtjew 24 ili vektor za upotrebu prema patentnom zahtjevu 25, naznačena time što je kancer kancer ovarijuma.
27. Upotreba proteina prema bilo kom od patentnih zahtjeva 1-8 u postupku za povećanje mišićne mase ili povećanje odnosa posne mišićne mase u odnosu na masu masti, pri čemu postupak nije postupak za lečenje ljudskog ili životinjskog tela pomoću terapije.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20025008P | 2008-11-26 | 2008-11-26 | |
| US25906009P | 2009-11-06 | 2009-11-06 | |
| EP09761055.4A EP2370463B1 (en) | 2008-11-26 | 2009-11-24 | A stabilized variant of activin iib receptor |
| PCT/US2009/006252 WO2010062383A2 (en) | 2008-11-26 | 2009-11-24 | Stabilized receptor polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02652B true ME02652B (me) | 2017-06-20 |
Family
ID=41693455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-243A ME02652B (me) | 2008-11-26 | 2009-11-24 | Stabilizovana varijanta aktivin iib receptora |
Country Status (37)
| Country | Link |
|---|---|
| US (5) | US8410043B2 (me) |
| EP (2) | EP3101029B1 (me) |
| JP (3) | JP5611222B2 (me) |
| KR (3) | KR20170105124A (me) |
| CN (2) | CN104371024A (me) |
| AR (1) | AR074397A1 (me) |
| AU (1) | AU2009320364B2 (me) |
| BR (1) | BRPI0920962A2 (me) |
| CA (2) | CA2743850C (me) |
| CL (1) | CL2011001239A1 (me) |
| CO (1) | CO6382163A2 (me) |
| CR (2) | CR20160443A (me) |
| CY (1) | CY1118754T1 (me) |
| DK (1) | DK2370463T3 (me) |
| EA (2) | EA201791940A3 (me) |
| ES (1) | ES2600491T3 (me) |
| HR (1) | HRP20161450T1 (me) |
| HU (1) | HUE032090T2 (me) |
| IL (2) | IL212773A (me) |
| LT (1) | LT2370463T (me) |
| MA (1) | MA32936B1 (me) |
| ME (1) | ME02652B (me) |
| MX (1) | MX2011005505A (me) |
| MY (1) | MY159483A (me) |
| NZ (2) | NZ604818A (me) |
| PE (2) | PE20120206A1 (me) |
| PL (1) | PL2370463T3 (me) |
| PT (1) | PT2370463T (me) |
| RS (1) | RS55369B1 (me) |
| SG (2) | SG10201703067QA (me) |
| SI (1) | SI2370463T1 (me) |
| SM (1) | SMT201600417B (me) |
| TN (1) | TN2011000238A1 (me) |
| TW (1) | TWI486166B (me) |
| UA (1) | UA107921C2 (me) |
| WO (1) | WO2010062383A2 (me) |
| ZA (1) | ZA201104648B (me) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| KR20190006086A (ko) | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| EP2111229B1 (en) | 2007-02-01 | 2013-04-10 | Acceleron Pharma, Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| ES2756725T3 (es) | 2007-02-09 | 2020-04-27 | Acceleron Pharma Inc | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| SMT202300222T1 (it) | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
| SG10201703067QA (en) * | 2008-11-26 | 2017-05-30 | Amgen Inc | Variants Of Activin IIB Receptor Polypeptides And Uses Thereof |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| AU2011276328C1 (en) * | 2010-07-06 | 2016-01-21 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| US8999343B2 (en) | 2010-08-16 | 2015-04-07 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| HK1203384A1 (en) * | 2011-12-19 | 2015-12-11 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| JP2015525230A (ja) | 2012-06-11 | 2015-09-03 | アムジエン・インコーポレーテツド | デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用 |
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| US20140220033A1 (en) * | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
| SG10201706148WA (en) | 2013-02-01 | 2017-08-30 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| CN104693270B (zh) * | 2013-12-10 | 2018-10-16 | 清华大学 | 一种用于融合蛋白的连接肽 |
| EP3094751A4 (en) * | 2014-01-14 | 2017-06-07 | Santa Maria Biotherapeutics, Inc. | Activin inhibitor response prediction and uses for treatment |
| WO2015192111A1 (en) | 2014-06-13 | 2015-12-17 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
| KR20170035891A (ko) * | 2014-06-13 | 2017-03-31 | 산타 마리아 바이오테라퓨틱스, 인코포레이티드 | 제형화된 수용체 폴리펩타이드 및 관련 방법 |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| KR102554850B1 (ko) | 2015-02-06 | 2023-07-13 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도 |
| US10227392B2 (en) | 2015-04-06 | 2019-03-12 | Acceleron Pharma Inc. | ALK7:ActRIIB heteromultimers and uses thereof |
| CN107849114B (zh) | 2015-04-06 | 2021-08-20 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| PT3286206T (pt) | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| JP6987072B2 (ja) | 2016-03-10 | 2021-12-22 | アクセレロン ファーマ インコーポレーテッド | アクチビン２型受容体結合タンパク質及びその使用 |
| BR112019006993A2 (pt) | 2016-10-05 | 2019-09-03 | Acceleron Pharma Inc | heteromultímeros de alk4:actriib e usos dos mesmos |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CN110430890B (zh) | 2016-11-10 | 2024-09-10 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| JP7405772B2 (ja) | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| CN109320597B (zh) * | 2018-10-26 | 2021-10-26 | 中国农业科学院特产研究所 | 狐亚科激活素a蛋白及其制备与应用 |
| IL296394A (en) | 2020-03-20 | 2022-11-01 | Keros Therapeutics Inc | Type ii activin receptor chimeras and methods of using them |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| US20250041385A1 (en) | 2021-12-10 | 2025-02-06 | Biogen Ma Inc. | Modified actrii proteins and methods of use thereof |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| AU702163B2 (en) | 1994-04-29 | 1999-02-18 | Creative Biomolecules, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| IL143034A0 (en) | 1998-11-13 | 2002-04-21 | Immunex Corp | Human tslp dna and polypeptides |
| AU772694B2 (en) | 1999-01-21 | 2004-05-06 | Metamorphix International, Inc. | Growth differentiation factor inhibitors and uses therefor |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| CN101287484B (zh) | 2002-12-20 | 2012-10-10 | 安姆根有限公司 | 抑制肌肉生长抑制素的结合剂 |
| BRPI0410927A (pt) | 2003-06-02 | 2006-06-27 | Wyeth Corp | métodos terapêuticos e profiláticos para distúrbios neuromusculares |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| ATE555133T1 (de) | 2003-11-13 | 2012-05-15 | Hanmi Holdings Co Ltd | Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung |
| EP1771470B1 (en) | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| AU2005272646A1 (en) | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| EA011879B1 (ru) | 2004-09-24 | 2009-06-30 | Эмджин Инк. | МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| CA2621371C (en) | 2005-09-07 | 2018-05-15 | Amgen Fremont Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| ZA200806837B (en) * | 2006-03-02 | 2009-11-25 | Ishihara Sangyo Kaisha | Solid herbicidal composition |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| DK2124999T3 (da) | 2006-12-18 | 2013-01-14 | Acceleron Pharma Inc | Activin-actrii antagonister og anvendelser til behandling af anæmi |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| US8501678B2 (en) * | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| TWI573802B (zh) * | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| ES2449753T3 (es) * | 2007-03-19 | 2014-03-21 | National Research Council Of Canada | Proteínas de fusión que comprenden dos dominios de unión tgf-beta |
| EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| KR20100090683A (ko) | 2007-11-09 | 2010-08-16 | 제넨테크, 인크. | 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법 |
| AU2009262970A1 (en) | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients |
| SMT202300222T1 (it) | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| SG10201703067QA (en) | 2008-11-26 | 2017-05-30 | Amgen Inc | Variants Of Activin IIB Receptor Polypeptides And Uses Thereof |
| US8138142B2 (en) | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
| JP5766179B2 (ja) | 2009-04-27 | 2015-08-19 | ノバルティス アーゲー | 筋肉増殖を増加させるための組成物および方法 |
| BRPI1010587A2 (pt) | 2009-06-08 | 2019-04-09 | Acceleron Pharma Inc. | métodos para aumentar adipócitos termogênicos |
| US20120295814A1 (en) | 2010-01-08 | 2012-11-22 | The Brigham And Women's Hospital, Inc. | CA-125 Immune Complexes as Biomarkers of Ovarian Cancer |
| WO2011123691A1 (en) | 2010-03-31 | 2011-10-06 | Keryx Biopharmaceuticals, Inc. | Perifosine and capecitabine as a combined treatment for cancer |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| WO2013106715A1 (en) | 2012-01-13 | 2013-07-18 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
| WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2009
- 2009-11-24 SG SG10201703067QA patent/SG10201703067QA/en unknown
- 2009-11-24 NZ NZ604818A patent/NZ604818A/en not_active IP Right Cessation
- 2009-11-24 EP EP16179980.4A patent/EP3101029B1/en active Active
- 2009-11-24 PT PT97610554T patent/PT2370463T/pt unknown
- 2009-11-24 SG SG2011037777A patent/SG171813A1/en unknown
- 2009-11-24 ES ES09761055.4T patent/ES2600491T3/es active Active
- 2009-11-24 MX MX2011005505A patent/MX2011005505A/es active IP Right Grant
- 2009-11-24 CR CR20160443A patent/CR20160443A/es unknown
- 2009-11-24 BR BRPI0920962A patent/BRPI0920962A2/pt not_active IP Right Cessation
- 2009-11-24 MY MYPI2011002346A patent/MY159483A/en unknown
- 2009-11-24 SI SI200931546A patent/SI2370463T1/sl unknown
- 2009-11-24 AR ARP090104527A patent/AR074397A1/es not_active Application Discontinuation
- 2009-11-24 HR HRP20161450TT patent/HRP20161450T1/hr unknown
- 2009-11-24 UA UAA201107872A patent/UA107921C2/ru unknown
- 2009-11-24 AU AU2009320364A patent/AU2009320364B2/en not_active Ceased
- 2009-11-24 LT LTEP09761055.4T patent/LT2370463T/lt unknown
- 2009-11-24 KR KR1020177025044A patent/KR20170105124A/ko not_active Abandoned
- 2009-11-24 MA MA33960A patent/MA32936B1/fr unknown
- 2009-11-24 PE PE2011001077A patent/PE20120206A1/es not_active Application Discontinuation
- 2009-11-24 EA EA201791940A patent/EA201791940A3/ru unknown
- 2009-11-24 NZ NZ627111A patent/NZ627111A/en not_active IP Right Cessation
- 2009-11-24 DK DK09761055.4T patent/DK2370463T3/en active
- 2009-11-24 EA EA201100832A patent/EA201100832A1/ru unknown
- 2009-11-24 WO PCT/US2009/006252 patent/WO2010062383A2/en not_active Ceased
- 2009-11-24 KR KR1020177007651A patent/KR101778134B1/ko not_active Expired - Fee Related
- 2009-11-24 ME MEP-2016-243A patent/ME02652B/me unknown
- 2009-11-24 HU HUE09761055A patent/HUE032090T2/en unknown
- 2009-11-24 PE PE2015000401A patent/PE20150680A1/es not_active Application Discontinuation
- 2009-11-24 CN CN201410462932.8A patent/CN104371024A/zh active Pending
- 2009-11-24 KR KR1020117014720A patent/KR101720143B1/ko not_active Expired - Fee Related
- 2009-11-24 CA CA2743850A patent/CA2743850C/en not_active Expired - Fee Related
- 2009-11-24 CA CA2997971A patent/CA2997971A1/en not_active Abandoned
- 2009-11-24 CN CN200980147945.3A patent/CN102245634B/zh not_active Expired - Fee Related
- 2009-11-24 EP EP09761055.4A patent/EP2370463B1/en active Active
- 2009-11-24 PL PL09761055T patent/PL2370463T3/pl unknown
- 2009-11-24 RS RS20160909A patent/RS55369B1/sr unknown
- 2009-11-24 JP JP2011538599A patent/JP5611222B2/ja not_active Expired - Fee Related
- 2009-11-25 US US12/626,375 patent/US8410043B2/en active Active
- 2009-11-26 TW TW098140431A patent/TWI486166B/zh not_active IP Right Cessation
-
2011
- 2011-05-08 IL IL212773A patent/IL212773A/en not_active IP Right Cessation
- 2011-05-12 TN TN2011000238A patent/TN2011000238A1/fr unknown
- 2011-05-26 CL CL2011001239A patent/CL2011001239A1/es unknown
- 2011-06-23 CO CO11079058A patent/CO6382163A2/es not_active Application Discontinuation
- 2011-06-23 ZA ZA2011/04648A patent/ZA201104648B/en unknown
- 2011-06-24 CR CR20110364A patent/CR20110364A/es unknown
-
2013
- 2013-02-25 US US13/775,756 patent/US9273114B2/en active Active
-
2014
- 2014-09-02 JP JP2014177598A patent/JP5969557B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-22 US US15/004,375 patent/US10308704B2/en active Active
- 2016-07-07 JP JP2016134684A patent/JP2016199577A/ja not_active Ceased
- 2016-09-29 IL IL248128A patent/IL248128A0/en unknown
- 2016-11-16 SM SM201600417T patent/SMT201600417B/it unknown
- 2016-11-16 CY CY20161101175T patent/CY1118754T1/el unknown
-
2019
- 2019-04-18 US US16/388,561 patent/US11685770B2/en active Active
-
2023
- 2023-06-07 US US18/206,963 patent/US20230295267A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02652B (me) | Stabilizovana varijanta aktivin iib receptora | |
| HRP20170323T1 (hr) | Dopunski aktivin receptor polipeptidi i njihove upotrebe | |
| JP2012509687A5 (me) | ||
| JP2010519931A5 (me) | ||
| JP2009513162A5 (me) | ||
| JP2006524034A5 (me) | ||
| ME02539B (me) | Antitijela protiv aktivina a i njegove prijmene | |
| HRP20211575T1 (hr) | Fuzijski proteini za liječenje metaboličkih poremećaja | |
| JP2013507930A5 (me) | ||
| CA2627200A1 (en) | Novel activin receptor and its uses in treating metabolic disorders | |
| JP2013107899A5 (me) | ||
| JP2015522576A5 (me) | ||
| RU2018118025A (ru) | Белки с двойной функцией и содержащая их фармацевтическая композиция | |
| JP2020531002A5 (me) | ||
| JP2020517635A5 (me) | ||
| JP2018528237A5 (me) | ||
| HRP20240996T1 (hr) | Prefuzija rsv f proteina i njihova uporaba | |
| RU2015142999A (ru) | Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения | |
| JP2014508510A5 (me) | ||
| JP2013501816A5 (me) | ||
| JP2011525363A5 (me) | ||
| HRP20201392T1 (hr) | Fgf21 fuzijski proteini dugotrajnog djelovanja i farmaceutski pripravci koji sadrže iste | |
| JP2017081939A5 (me) | ||
| HRP20200503T1 (hr) | Fuzijski proteini | |
| JP2017523789A5 (me) |